YM-53601 suppresses cholesterol biosynthesis in rats (ED50, 32mg/kg)[1].
YM-53601 also reduces plasma non-HDL cholesterol levels in hamsters by approximately 70% at an oral dose of 50 mg/kg/day for 5 days[2].
YM-53601 potentiates Doxorubicin-mediated hepatocellular carcinoma cells (HCC) growth arrest and cell death in vivo[4].
| Animal Model: | Sprague-Dawley (SD) rats weighing 150-170g[1] |
| Dosage: | 6.25, 12.5, 25 or 50mg/kg |
| Administration: | Given a single p.o. |
| Result: | Inhibited cholesterol biosynthesis from acetate in a dose-dependent manner in rats. The ED50value for YM-53601 cholesterol biosynthesis inhibition is 32 mg/kg.
|
| Animal Model: | Five- to six-week-old male BALB/c athymic (nu/nu) nude mice[4] |
| Dosage: | 15 mg/kg |
| Administration: | 2 wk of daily treatment by p.o. gavage |
| Result: | Significantly decreased the intratumor cholesterol levels.
|
